CEO of For-Profit MA Plan Tells CMS “Pay Us Less”

Why It Matters

If CMS reduces MA payments, it could reshape funding models for a market that now covers over half of Medicare beneficiaries, affecting both federal spending and private‑sector profitability.

Key Takeaways

• Devoted Health CEO urges CMS to lower Medicare Advantage payments.
• MedPAC reports MA plans cost CMS $76 billion more than traditional Medicare.
• PMPM benefits jumped $91, from $120 (2021) to $211 (2022).
• CEO’s stance may upset AHIP and other Medicare Advantage lobbyists.

Pulse Analysis

Medicare Advantage has become the dominant enrollment option for seniors, now covering more than 50% of beneficiaries. Yet the program’s cost advantage remains elusive; MedPAC’s latest analysis estimates an additional $76 billion in spending compared with traditional fee‑for‑service Medicare. The discrepancy fuels a policy debate over whether the risk‑adjusted payments to private plans are inflated or whether the higher costs reflect expanded benefit packages and administrative efficiencies. Understanding this fiscal gap is crucial for stakeholders ranging from policymakers to investors watching the health‑care market’s bottom line.

At the annual Medicarians conference, Devoted Health’s Ed Park turned the usual lobbying script on its head by publicly urging the Centers for Medicare & Medicaid Services to cut MA payments. Park argued that the system already has enough surplus to fund both comprehensive senior care and national debt reduction, pointing to a $91 per‑member‑per‑month rise in benefit value between 2021 and 2022. His comments underscore a growing confidence among some for‑profit MA operators that operational efficiencies and innovation can offset lower reimbursements, especially as the V28 risk‑adjustment model reshapes payment calculations.

The CEO’s candid stance is likely to provoke a strong response from industry groups such as the American Health Insurance Plans (AHIP), which traditionally lobby for higher rates. Investors, however, may view the narrative as a signal of disciplined capital management, potentially enhancing Devoted Health’s valuation amid a competitive fundraising environment. If CMS adopts a more restrained payment trajectory, the MA landscape could see tighter margins, prompting consolidation or a shift toward value‑based care models. The unfolding dialogue will shape federal health‑care spending and the strategic direction of private MA plans for years to come.